Buspirone as an antidote to venlafaxine-induced bruxism.
Jaffee
M S
MS
Ehrling Bergquist USAF Hospital, University of Nebraska Medical Center, USA.
Bostwick
J M
JM
D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage / Q000009:adverse effects*; D001714:Bipolar Disorder / Q000188:drug therapy*; D002012:Bruxism / Q000139:chemically induced* / Q000188:drug therapy; D002065:Buspirone / Q000008:administration & dosage*; D003511:Cyclohexanols / Q000008:administration & dosage / Q000009:adverse effects*; D003865:Major Depressive Disorder / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D000069470:Venlafaxine Hydrochloride
D018687:Antidepressive Agents, Second-Generation; D003511:Cyclohexanols; D000069470:Venlafaxine Hydrochloride; D002065:Buspirone